COSMOG CLINICAL TRIAL UPDATE
The CosMOG clinical trial is no longer enrolling participants. This page remains available to help you learn about the study, stay informed about updates, and guide to other MOGAD clinical trial opportunities.
Sponsored by UCB Biopharma SRL
The CosMOG study evaluates the efficacy of Rozanolixizumab as a preventative treatment for relapsing MOG Antibody Disease. While enrollment for this study has closed, the research remains an important step toward better treatments for the MOGAD community.
Stay Informed & Explore Options
The US government provides a website that lists all of the current running clinical trials in the US that patients, caregivers, and medical professionals can reference. Below is a link to the entry for the CosMOG study, or CosMOG Clinical Trial:
Through an organization working with UCB called KnowRare, you can connect to someone who can provide answers to questions and get help connecting with specialists running the CosMOG clinical trial.
If you’re interested in:
- Learning about updates related to CosMOG
- Connecting with clinicians familiar with this research
- Exploring other clinical trials or treatment options
Our team is here to help.
WATCH THESE VIDEOS WE CREATED TO HELP YOU UNDERSTAND THE COSMOG TRIAL
The two videos below provide a great review of what Rozanolixizumab does, as well as a friendly discussion with Dr. Michael Levy and two MOGAD patients who are currently in the clinical trial.
The Latest From The MOG Initiative
CosMOG Over Coffee: The Patient Perspective
Use this form to ask questions, receive updates, or connect with experts who can help you better understand this research and other potential options.
Our team is here to support you in understanding clinical research and navigating next steps. We can help you learn more about CosMOG and identify other MOGAD clinical trials that may be available.
Looking for active studies? Visit our MOGAD Clinical Trials page to explore current opportunities.